WO2007105264A1 - 新規ホスホリパーゼc - Google Patents
新規ホスホリパーゼc Download PDFInfo
- Publication number
- WO2007105264A1 WO2007105264A1 PCT/JP2006/304710 JP2006304710W WO2007105264A1 WO 2007105264 A1 WO2007105264 A1 WO 2007105264A1 JP 2006304710 W JP2006304710 W JP 2006304710W WO 2007105264 A1 WO2007105264 A1 WO 2007105264A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- phospholipase
- activity
- strain
- aspergillus
- protein
- Prior art date
Links
- 108010079194 Type C Phospholipases Proteins 0.000 title claims abstract description 152
- 102000014384 Type C Phospholipases Human genes 0.000 title claims abstract description 150
- 230000000694 effects Effects 0.000 claims abstract description 130
- 150000003904 phospholipids Chemical class 0.000 claims abstract description 34
- 230000002378 acidificating effect Effects 0.000 claims abstract description 17
- 230000003301 hydrolyzing effect Effects 0.000 claims abstract description 17
- 229910019142 PO4 Inorganic materials 0.000 claims abstract description 11
- 230000007935 neutral effect Effects 0.000 claims abstract description 10
- 239000010452 phosphate Substances 0.000 claims abstract description 9
- 108090000623 proteins and genes Proteins 0.000 claims description 56
- 102000004169 proteins and genes Human genes 0.000 claims description 48
- 240000006439 Aspergillus oryzae Species 0.000 claims description 46
- 108010000912 Egg Proteins Proteins 0.000 claims description 46
- 102000002322 Egg Proteins Human genes 0.000 claims description 46
- 210000002969 egg yolk Anatomy 0.000 claims description 46
- 235000013345 egg yolk Nutrition 0.000 claims description 46
- 235000002247 Aspergillus oryzae Nutrition 0.000 claims description 45
- 108020004414 DNA Proteins 0.000 claims description 41
- 102000015439 Phospholipases Human genes 0.000 claims description 34
- 108010064785 Phospholipases Proteins 0.000 claims description 34
- 150000001413 amino acids Chemical class 0.000 claims description 34
- ZIIUUSVHCHPIQD-UHFFFAOYSA-N 2,4,6-trimethyl-N-[3-(trifluoromethyl)phenyl]benzenesulfonamide Chemical compound CC1=CC(C)=CC(C)=C1S(=O)(=O)NC1=CC=CC(C(F)(F)F)=C1 ZIIUUSVHCHPIQD-UHFFFAOYSA-N 0.000 claims description 33
- 239000000787 lecithin Substances 0.000 claims description 33
- 235000010445 lecithin Nutrition 0.000 claims description 33
- 238000000034 method Methods 0.000 claims description 33
- 238000006460 hydrolysis reaction Methods 0.000 claims description 32
- 229940067606 lecithin Drugs 0.000 claims description 32
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims description 31
- 230000007062 hydrolysis Effects 0.000 claims description 31
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims description 29
- 241000134719 Aspergillus tamarii Species 0.000 claims description 26
- 239000002773 nucleotide Substances 0.000 claims description 18
- 125000003729 nucleotide group Chemical group 0.000 claims description 18
- 150000003905 phosphatidylinositols Chemical class 0.000 claims description 17
- 241000233866 Fungi Species 0.000 claims description 14
- 241000228212 Aspergillus Species 0.000 claims description 12
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 claims description 12
- 150000008104 phosphatidylethanolamines Chemical class 0.000 claims description 12
- ATBOMIWRCZXYSZ-XZBBILGWSA-N [1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-hexadecanoyloxypropan-2-yl] (9e,12e)-octadeca-9,12-dienoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC ATBOMIWRCZXYSZ-XZBBILGWSA-N 0.000 claims description 9
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 claims description 9
- 235000021317 phosphate Nutrition 0.000 claims description 9
- 108091026890 Coding region Proteins 0.000 claims description 8
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 claims description 7
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 claims description 6
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 6
- 238000001962 electrophoresis Methods 0.000 claims description 5
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 claims description 5
- 230000008569 process Effects 0.000 claims description 3
- 150000003013 phosphoric acid derivatives Chemical class 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 5
- 239000000243 solution Substances 0.000 abstract description 52
- 239000007979 citrate buffer Substances 0.000 abstract description 11
- -1 phosphate ester Chemical class 0.000 abstract description 11
- 150000002632 lipids Chemical group 0.000 abstract description 2
- 102000004190 Enzymes Human genes 0.000 description 72
- 108090000790 Enzymes Proteins 0.000 description 72
- 229940088598 enzyme Drugs 0.000 description 72
- 210000004027 cell Anatomy 0.000 description 45
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 40
- 239000002609 medium Substances 0.000 description 38
- 235000018102 proteins Nutrition 0.000 description 36
- 239000000872 buffer Substances 0.000 description 32
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 24
- 244000068988 Glycine max Species 0.000 description 23
- 235000010469 Glycine max Nutrition 0.000 description 23
- 235000013305 food Nutrition 0.000 description 20
- 239000007983 Tris buffer Substances 0.000 description 19
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 19
- 241000894006 Bacteria Species 0.000 description 18
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 17
- 230000015556 catabolic process Effects 0.000 description 16
- 238000006731 degradation reaction Methods 0.000 description 16
- 239000000758 substrate Substances 0.000 description 16
- 239000013598 vector Substances 0.000 description 16
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 15
- 238000012360 testing method Methods 0.000 description 15
- 238000006911 enzymatic reaction Methods 0.000 description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- 239000011780 sodium chloride Substances 0.000 description 12
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 10
- 244000005700 microbiome Species 0.000 description 10
- 239000000203 mixture Substances 0.000 description 10
- 238000011282 treatment Methods 0.000 description 10
- PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 description 9
- 229920001817 Agar Polymers 0.000 description 9
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 9
- 239000008272 agar Substances 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 239000013612 plasmid Substances 0.000 description 8
- 238000000746 purification Methods 0.000 description 8
- 238000005259 measurement Methods 0.000 description 7
- YHHSONZFOIEMCP-UHFFFAOYSA-O phosphocholine Chemical compound C[N+](C)(C)CCOP(O)(O)=O YHHSONZFOIEMCP-UHFFFAOYSA-O 0.000 description 7
- LFGREXWGYUGZLY-UHFFFAOYSA-N phosphoryl Chemical group [P]=O LFGREXWGYUGZLY-UHFFFAOYSA-N 0.000 description 7
- 229950004354 phosphorylcholine Drugs 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 229930006000 Sucrose Natural products 0.000 description 6
- 235000001014 amino acid Nutrition 0.000 description 6
- 239000012153 distilled water Substances 0.000 description 6
- 239000013604 expression vector Substances 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 239000005720 sucrose Substances 0.000 description 6
- JQWAHKMIYCERGA-UHFFFAOYSA-N (2-nonanoyloxy-3-octadeca-9,12-dienoyloxypropoxy)-[2-(trimethylazaniumyl)ethyl]phosphinate Chemical compound CCCCCCCCC(=O)OC(COP([O-])(=O)CC[N+](C)(C)C)COC(=O)CCCCCCCC=CCC=CCCCCC JQWAHKMIYCERGA-UHFFFAOYSA-N 0.000 description 5
- 241000588724 Escherichia coli Species 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 108091028043 Nucleic acid sequence Proteins 0.000 description 5
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 5
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 5
- 238000005119 centrifugation Methods 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 238000010828 elution Methods 0.000 description 5
- 238000000691 measurement method Methods 0.000 description 5
- 229910052757 nitrogen Inorganic materials 0.000 description 5
- 239000003921 oil Substances 0.000 description 5
- 235000019198 oils Nutrition 0.000 description 5
- 150000003014 phosphoric acid esters Chemical class 0.000 description 5
- RYCNUMLMNKHWPZ-SNVBAGLBSA-N 1-acetyl-sn-glycero-3-phosphocholine Chemical compound CC(=O)OC[C@@H](O)COP([O-])(=O)OCC[N+](C)(C)C RYCNUMLMNKHWPZ-SNVBAGLBSA-N 0.000 description 4
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 4
- XZKIHKMTEMTJQX-UHFFFAOYSA-N 4-Nitrophenyl Phosphate Chemical compound OP(O)(=O)OC1=CC=C([N+]([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-N 0.000 description 4
- 241000186361 Actinobacteria <class> Species 0.000 description 4
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 4
- 229910000013 Ammonium bicarbonate Inorganic materials 0.000 description 4
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 description 4
- 235000019733 Fish meal Nutrition 0.000 description 4
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
- 108010076504 Protein Sorting Signals Proteins 0.000 description 4
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 4
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 4
- 235000012538 ammonium bicarbonate Nutrition 0.000 description 4
- 239000001099 ammonium carbonate Substances 0.000 description 4
- 229940041514 candida albicans extract Drugs 0.000 description 4
- 229940106189 ceramide Drugs 0.000 description 4
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 description 4
- 239000012141 concentrate Substances 0.000 description 4
- 238000012258 culturing Methods 0.000 description 4
- 229960003964 deoxycholic acid Drugs 0.000 description 4
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 4
- 239000004467 fishmeal Substances 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- 239000012138 yeast extract Substances 0.000 description 4
- ASWBNKHCZGQVJV-UHFFFAOYSA-N (3-hexadecanoyloxy-2-hydroxypropyl) 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(O)COP([O-])(=O)OCC[N+](C)(C)C ASWBNKHCZGQVJV-UHFFFAOYSA-N 0.000 description 3
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 3
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 3
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 3
- 244000063299 Bacillus subtilis Species 0.000 description 3
- 235000014469 Bacillus subtilis Nutrition 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 102000000588 Interleukin-2 Human genes 0.000 description 3
- 108010002350 Interleukin-2 Proteins 0.000 description 3
- 102000004882 Lipase Human genes 0.000 description 3
- 108090001060 Lipase Proteins 0.000 description 3
- 239000004367 Lipase Substances 0.000 description 3
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 description 3
- 241000576755 Sclerotia Species 0.000 description 3
- 102000004142 Trypsin Human genes 0.000 description 3
- 108090000631 Trypsin Proteins 0.000 description 3
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 239000012228 culture supernatant Substances 0.000 description 3
- 230000000593 degrading effect Effects 0.000 description 3
- 150000001982 diacylglycerols Chemical class 0.000 description 3
- 239000008157 edible vegetable oil Substances 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 210000003527 eukaryotic cell Anatomy 0.000 description 3
- 210000000416 exudates and transudate Anatomy 0.000 description 3
- 235000019421 lipase Nutrition 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 150000007523 nucleic acids Chemical class 0.000 description 3
- 239000003208 petroleum Substances 0.000 description 3
- 239000000049 pigment Substances 0.000 description 3
- 239000012588 trypsin Substances 0.000 description 3
- 238000000108 ultra-filtration Methods 0.000 description 3
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- IVLXQGJVBGMLRR-UHFFFAOYSA-N 2-aminoacetic acid;hydron;chloride Chemical compound Cl.NCC(O)=O IVLXQGJVBGMLRR-UHFFFAOYSA-N 0.000 description 2
- JIRDGRJQDQDHIV-UHFFFAOYSA-N 2-hydroxyethyl-dimethyl-[(oxo-$l^{5}-phosphanylidyne)methyl]azanium;propane-1,2,3-triol Chemical compound OCC(O)CO.OCC[N+](C)(C)C#P=O JIRDGRJQDQDHIV-UHFFFAOYSA-N 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- KBKGRMNVKPSQIF-XDTLVQLUSA-N Glu-Ala-Tyr Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O KBKGRMNVKPSQIF-XDTLVQLUSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 2
- 241000238631 Hexapoda Species 0.000 description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
- 239000007993 MOPS buffer Substances 0.000 description 2
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 239000001888 Peptone Substances 0.000 description 2
- 108010080698 Peptones Proteins 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 108020005067 RNA Splice Sites Proteins 0.000 description 2
- 108020005091 Replication Origin Proteins 0.000 description 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 2
- 238000012300 Sequence Analysis Methods 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- 239000013504 Triton X-100 Substances 0.000 description 2
- 229920004890 Triton X-100 Polymers 0.000 description 2
- 102000001400 Tryptase Human genes 0.000 description 2
- 108060005989 Tryptase Proteins 0.000 description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 2
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 2
- 229960001231 choline Drugs 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 235000012343 cottonseed oil Nutrition 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 235000013373 food additive Nutrition 0.000 description 2
- 239000002778 food additive Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 2
- 229960000367 inositol Drugs 0.000 description 2
- 238000004255 ion exchange chromatography Methods 0.000 description 2
- 238000009630 liquid culture Methods 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
- 235000019341 magnesium sulphate Nutrition 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 235000019319 peptone Nutrition 0.000 description 2
- 230000000704 physical effect Effects 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 210000001236 prokaryotic cell Anatomy 0.000 description 2
- 230000035484 reaction time Effects 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 2
- 230000003248 secreting effect Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 230000005030 transcription termination Effects 0.000 description 2
- 241000701447 unidentified baculovirus Species 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- BRZYSWJRSDMWLG-DJWUNRQOSA-N (2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2s,3r,4r,5s,6r)-3-amino-4,5-dihydroxy-6-[(1r)-1-hydroxyethyl]oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H]([C@@H](C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-DJWUNRQOSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 1
- PZNPLUBHRSSFHT-RRHRGVEJSA-N 1-hexadecanoyl-2-octadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)COC(=O)CCCCCCCCCCCCCCC PZNPLUBHRSSFHT-RRHRGVEJSA-N 0.000 description 1
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 1
- PAWQVTBBRAZDMG-UHFFFAOYSA-N 2-(3-bromo-2-fluorophenyl)acetic acid Chemical compound OC(=O)CC1=CC=CC(Br)=C1F PAWQVTBBRAZDMG-UHFFFAOYSA-N 0.000 description 1
- BTJIUGUIPKRLHP-UHFFFAOYSA-N 4-nitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1 BTJIUGUIPKRLHP-UHFFFAOYSA-N 0.000 description 1
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 239000004382 Amylase Substances 0.000 description 1
- 102000013142 Amylases Human genes 0.000 description 1
- 108010065511 Amylases Proteins 0.000 description 1
- 241000228245 Aspergillus niger Species 0.000 description 1
- 241000228251 Aspergillus phoenicis Species 0.000 description 1
- 101100335652 Autographa californica nuclear polyhedrosis virus GP64 gene Proteins 0.000 description 1
- 241000193755 Bacillus cereus Species 0.000 description 1
- 108700040077 Baculovirus p10 Proteins 0.000 description 1
- 240000002791 Brassica napus Species 0.000 description 1
- 235000004977 Brassica sinapistrum Nutrition 0.000 description 1
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 1
- 101001007681 Candida albicans (strain WO-1) Kexin Proteins 0.000 description 1
- 102000003846 Carbonic anhydrases Human genes 0.000 description 1
- 108090000209 Carbonic anhydrases Proteins 0.000 description 1
- 241000193468 Clostridium perfringens Species 0.000 description 1
- 241001478240 Coccus Species 0.000 description 1
- 108700010070 Codon Usage Proteins 0.000 description 1
- GUBGYTABKSRVRQ-CUHNMECISA-N D-Cellobiose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-CUHNMECISA-N 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 101150010917 GP67 gene Proteins 0.000 description 1
- UXDDRFCJKNROTO-UHFFFAOYSA-N Glycerol 1,2-diacetate Chemical compound CC(=O)OCC(CO)OC(C)=O UXDDRFCJKNROTO-UHFFFAOYSA-N 0.000 description 1
- 241000235058 Komagataella pastoris Species 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000255777 Lepidoptera Species 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 241000108056 Monas Species 0.000 description 1
- 241001045988 Neogene Species 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 108010058846 Ovalbumin Proteins 0.000 description 1
- 102000008153 Peptide Elongation Factor Tu Human genes 0.000 description 1
- 108010049977 Peptide Elongation Factor Tu Proteins 0.000 description 1
- 102000000447 Peptide-N4-(N-acetyl-beta-glucosaminyl) Asparagine Amidase Human genes 0.000 description 1
- 108010055817 Peptide-N4-(N-acetyl-beta-glucosaminyl) Asparagine Amidase Proteins 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 description 1
- 102000011420 Phospholipase D Human genes 0.000 description 1
- 108090000553 Phospholipase D Proteins 0.000 description 1
- 102000000571 Phospholipases A Human genes 0.000 description 1
- 108010002176 Phospholipases A Proteins 0.000 description 1
- 102000009097 Phosphorylases Human genes 0.000 description 1
- 108010073135 Phosphorylases Proteins 0.000 description 1
- 101710182846 Polyhedrin Proteins 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- BJCXXMGGPHRSHV-GUBZILKMSA-N Pro-Ser-Met Chemical compound CSCC[C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H]1CCCN1 BJCXXMGGPHRSHV-GUBZILKMSA-N 0.000 description 1
- 101710093543 Probable non-specific lipid-transfer protein Proteins 0.000 description 1
- 235000014443 Pyrus communis Nutrition 0.000 description 1
- 238000012181 QIAquick gel extraction kit Methods 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 235000019484 Rapeseed oil Nutrition 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- 108010022999 Serine Proteases Proteins 0.000 description 1
- 102000012479 Serine Proteases Human genes 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 240000006394 Sorghum bicolor Species 0.000 description 1
- 235000011684 Sorghum saccharatum Nutrition 0.000 description 1
- 241000256248 Spodoptera Species 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 241000187747 Streptomyces Species 0.000 description 1
- 108010022394 Threonine synthase Proteins 0.000 description 1
- 241000255993 Trichoplusia ni Species 0.000 description 1
- 101710162629 Trypsin inhibitor Proteins 0.000 description 1
- 229940122618 Trypsin inhibitor Drugs 0.000 description 1
- DOFAQXCYFQKSHT-SRVKXCTJSA-N Val-Pro-Pro Chemical compound CC(C)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(O)=O)CCC1 DOFAQXCYFQKSHT-SRVKXCTJSA-N 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 238000005377 adsorption chromatography Methods 0.000 description 1
- 238000005273 aeration Methods 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 235000019418 amylase Nutrition 0.000 description 1
- 210000001557 animal structure Anatomy 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000000721 bacterilogical effect Effects 0.000 description 1
- LFYJSSARVMHQJB-QIXNEVBVSA-N bakuchiol Chemical compound CC(C)=CCC[C@@](C)(C=C)\C=C\C1=CC=C(O)C=C1 LFYJSSARVMHQJB-QIXNEVBVSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- RUDATBOHQWOJDD-BSWAIDMHSA-N chenodeoxycholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 RUDATBOHQWOJDD-BSWAIDMHSA-N 0.000 description 1
- 229960001091 chenodeoxycholic acid Drugs 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000018842 conidium formation Effects 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 239000010779 crude oil Substances 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 239000006787 czapek-dox agar Substances 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000011033 desalting Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 229940079919 digestives enzyme preparation Drugs 0.000 description 1
- 102000004419 dihydrofolate reductase Human genes 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- KAKKHKRHCKCAGH-UHFFFAOYSA-L disodium;(4-nitrophenyl) phosphate;hexahydrate Chemical compound O.O.O.O.O.O.[Na+].[Na+].[O-][N+](=O)C1=CC=C(OP([O-])([O-])=O)C=C1 KAKKHKRHCKCAGH-UHFFFAOYSA-L 0.000 description 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000003028 enzyme activity measurement method Methods 0.000 description 1
- ZINJLDJMHCUBIP-UHFFFAOYSA-N ethametsulfuron-methyl Chemical compound CCOC1=NC(NC)=NC(NC(=O)NS(=O)(=O)C=2C(=CC=CC=2)C(=O)OC)=N1 ZINJLDJMHCUBIP-UHFFFAOYSA-N 0.000 description 1
- 229940031098 ethanolamine Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 108010092809 exonuclease Bal 31 Proteins 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 235000013350 formula milk Nutrition 0.000 description 1
- 235000012470 frozen dough Nutrition 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 229960005150 glycerol Drugs 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 235000020256 human milk Nutrition 0.000 description 1
- 210000004251 human milk Anatomy 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 239000004570 mortar (masonry) Substances 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 101150091879 neo gene Proteins 0.000 description 1
- 125000001477 organic nitrogen group Chemical group 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 229940092253 ovalbumin Drugs 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-M phenolate Chemical compound [O-]C1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-M 0.000 description 1
- 229940031826 phenolate Drugs 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 125000001095 phosphatidyl group Chemical group 0.000 description 1
- 150000004713 phosphodiesters Chemical class 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229920002477 rna polymer Polymers 0.000 description 1
- 229940081969 saccharomyces cerevisiae Drugs 0.000 description 1
- 238000005185 salting out Methods 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 229960001153 serine Drugs 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 239000007974 sodium acetate buffer Substances 0.000 description 1
- BHZOKUMUHVTPBX-UHFFFAOYSA-M sodium acetic acid acetate Chemical compound [Na+].CC(O)=O.CC([O-])=O BHZOKUMUHVTPBX-UHFFFAOYSA-M 0.000 description 1
- NRHMKIHPTBHXPF-TUJRSCDTSA-M sodium cholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 NRHMKIHPTBHXPF-TUJRSCDTSA-M 0.000 description 1
- OESFSXYRSCBAQJ-UHFFFAOYSA-M sodium;3-carboxy-3,5-dihydroxy-5-oxopentanoate;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound [Na+].OC(=O)CC(O)(C(O)=O)CC(O)=O.OC(=O)CC(O)(C(O)=O)CC([O-])=O OESFSXYRSCBAQJ-UHFFFAOYSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 229940083466 soybean lecithin Drugs 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 239000008347 soybean phospholipid Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 239000002753 trypsin inhibitor Substances 0.000 description 1
- 241000701366 unidentified nuclear polyhedrosis viruses Species 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 108010015385 valyl-prolyl-proline Proteins 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 210000002268 wool Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/18—Carboxylic ester hydrolases (3.1.1)
- C12N9/20—Triglyceride splitting, e.g. by means of lipase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/14—Fungi; Culture media therefor
- C12N1/145—Fungal isolates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P7/00—Preparation of oxygen-containing organic compounds
- C12P7/64—Fats; Fatty oils; Ester-type waxes; Higher fatty acids, i.e. having at least seven carbon atoms in an unbroken chain bound to a carboxyl group; Oxidised oils or fats
- C12P7/6409—Fatty acids
- C12P7/6418—Fatty acids by hydrolysis of fatty acid esters
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P7/00—Preparation of oxygen-containing organic compounds
- C12P7/64—Fats; Fatty oils; Ester-type waxes; Higher fatty acids, i.e. having at least seven carbon atoms in an unbroken chain bound to a carboxyl group; Oxidised oils or fats
- C12P7/6436—Fatty acid esters
- C12P7/6445—Glycerides
- C12P7/6481—Phosphoglycerides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/645—Fungi ; Processes using fungi
- C12R2001/66—Aspergillus
- C12R2001/69—Aspergillus oryzae
Definitions
- the present invention relates to a phospholipase, a filamentous fungus that produces the phospholipase C, a method for separating and purifying the phospholipase C from a culture of the fungus, a DNA encoding the phospholipase C, and a method for producing the phospholipase C. Etc.
- the present invention relates to a phospholipase particularly suitable for use in the food and pharmaceutical industries, in particular the fungus Aspergillus oryzae, or the phospholipase produced by Aspergill us tamarii,
- the present invention relates to a filamentous fungus producing the phospholipase C, the ability to culture the filamentous fungus, a method of separating and purifying the phospholipase C, a DNA encoding the phospholipase C, a method of producing the phospholipase C, and the like.
- phospholipase C Traditionally, it is known that animals and microorganisms produce phospholipase C.
- the animal-derived enzyme is mainly phosphatidylinositol-selective phospholipase c.
- phospholipase C derived from bacteria, actinomycetes, yeasts and molds is known. Most phospholipases C produced by bacteria, actinomycetes and yeasts are phosphatidyl inositol selective or phosphatidyl choline selective.
- Examples of phospholipase C derived from bacteria include, for example, Syudu Monas' Surkyllensis.
- Patent Document 1 JP 50-1017183 A
- Bullholderia pseudomallei for example, Non-Patent Document 1: Korbsrisate S. et. Al.
- Bacillus cereus for example, Non-Patent Document 2: Tan C. et. Al., “Protein Expression and Purification” (Protein Expression and Purification) 1997, 10 ⁇ , p. 365-372
- Staphylococcus' Sauphylo coccus aureus eg, Non-Patent Document 3: Daugherty S.
- Non-Patent Document 4 Tateval et al. ( Titball R. et. Al.) “Infection and Immunity” (1989, 57 ⁇ , p.367-376) etc. are known.
- phospholipase C derived from actinomycetes
- phospholipase C produced by Streptomyces hachijyoensis see, for example, Patent Document 2: Japanese Patent Laid-Open No. 49 55893 is known. .
- Examples of phospholipase C derived from yeast include, for example, Candida a lbicans (for example, Non-Patent Document 5: Andaluz E. et. Al. “Yeast” 2 001, 18 ⁇ , P.711-721), Saccharomyces cere visiae (eg, Non-Patent Document 6: Payne W. et. Al. “Molecular ⁇ ⁇ and 'Serula ⁇ ⁇ ⁇ Biology ”(Molecular and Cellular Biology) 1993, 13 ⁇ , p.4351- 4364) etc. is known.
- Candida a lbicans for example, Non-Patent Document 5: Andaluz E. et. Al. “Yeast” 2 001, 18 ⁇ , P.711-721
- Saccharomyces cere visiae eg, Non-Patent Document 6: Payne W. et. Al. “Molecular ⁇ ⁇ and 'Serula ⁇ ⁇ ⁇ Biology
- Lecithin is a typical glyceport phospholipid widely distributed in animals, plants and fungi.
- Glyce mouth phospholipids are compounds in which a phosphoryl base is covalently bonded to position 3 of 1,2 diacylglycerol.
- Bases include choline, ethanolamine, serine, inositol, glycerol, and the like, and the composition ratio varies depending on the origin.
- Lecithin is used as a concept contained in glyceport phospholipids.
- Lecithin has a surface active action, an antioxidant action, a physiologically active action, and the like, and is used in foods, feeds, pharmaceuticals, and the like.
- egg yolk lecithin and soy lecithin Natural lecithins such as those are used as food additives and are mainly used as emulsifiers, etc. to modify the properties of foods and are supplied in abundance.
- Phospholipase A selectively hydrolyzes the 1st or 2nd fatty acid of glyceport phospholipids.
- Non-selective hydrolysis is phospholipase, hydrolyzing to diacylglycerol and phosphoryl base is phospholipase, and phospholipase D is degrading to phosphatidic acid and base.
- phospholipase A In the field of the food industry, phospholipase A is currently most frequently used. The ability of lecithin to be sparingly soluble in water When phospholipase A is allowed to act on lecithin, the acyl group is partially hydrolyzed to produce water-soluble lysolecithin. When lysolecithin is used as a food additive, the physical properties of the obtained food may be different from those of foods that have been obtained using lecithin.
- Sphingophospholipids constitute phospholipids together with glyceguchi phospholipids.
- a typical example of sphingophospholipids is sphingomyelin, which is a mixture of ceramide primary alcohol with phosphoric acid linked to phosphoric acid diester. It is widely contained in animal organs. Since it is also contained in breast milk, it may be blended into infant formula.
- Ceramide is widely used in cosmetics as a moisturizing ingredient. There is also a report that atopic dermatitis is caused by a lack of ceramide.
- diacylglycerol can be produced from lecithin in the presence of water as shown in the figure below. ——
- R and R are each an alkyl group, R is choline, ethanolamine, dari
- the phospholipase C used here is required to hydrolyze various glyceport phospholipids.
- soybean lecithin mainly contains phosphatidylcholine and phosphatidylethanolamine, and phosphatidylglycerol or phosphatidylinositol.
- Egg yolk-derived lecithin mainly contains phosphatidylcholine and phosphatidylethanolamine. Therefore, it is desirable that the phospholipase C used is hydrolyzed without discrimination.
- phospholipase C which does not hydrolyze phospholipids other than phospholipids, is desirable, for example, phospholipase C, which is similar to phospholipids but does not contain a lipid moiety, such as glycerin phosphorylcholine. Is desired.
- the phospholipase C used is preferably a protein having no phosphatase activity. That is, para-trophe, which is a substrate for phosphatase
- -Phospholipase C is preferred, which does not have ruphosphate-degrading activity.
- an enzyme agent containing phospholipase or the like which is preferably subjected to various treatments in a weakly acidic range with a neutral force to prevent the alteration of food, has high activity in this pH range. It is hoped that
- phospholipase C Use of phospholipase C in the food industry
- Applications of phospholipase c include, for example, aging that occurs on the surface of frozen frozen dough for baking, mitigating pear skin, and improving edible oil purification processes.
- Lecithin is a substance that should be removed because soybean rapeseed isotope also causes coloring or deterioration of the taste when producing edible oil.
- a method has been studied in which lecithin is partially hydrolyzed using phospholipase A to make it soluble in water by using lysolecithin.
- Phospholipase C used here is required to hydrolyze various phospholipids.
- soybean oil contains the various phospholipids described above.
- various phospholipids are contained in cottonseed oil or rapeseed oil.
- Phospholipase C used is desired to hydrolyze these without distinction U ,.
- Phospholipase c produced by animals, bacteria, actinomycetes or yeast is mainly selective for phosphatidylinositol or phosphatidylcholine and is not suitable for use in the food industry where various substrates need to be degraded. Furthermore, there are countries and regions where animal-derived enzyme preparations are not accepted religiously, and there is a problem with their versatility. In addition, most of the bacteria that produce phospholipase c are pathogenic and have safety issues.
- the conventionally known filamentous fungus-derived phospholipase C has a property of hydrolyzing various phospholipids.
- any filamentous fungus conventionally used for the production of phospholipase C has a characteristic of producing edible enzymes.
- Aspergillus The temperature and pH properties of the enzymes from both strains of Spergillus and Cytoi are very similar and have the same molecular weight. Each of them has a strong activity on the acidic side, but has a feature that there is no activity at all in the vicinity of neutrality. Therefore, in the refinery industry where these enzymes may be used on the acidic side, these enzymes may be usable.
- phospholipase C produced by Aspergillus gar has a very high degradation activity of phosphatidic acid, which is a phosphatase substrate (see Patent Document 3). Therefore, since the enzyme has the ability to hydrolyze phosphate monoesters, it is presumed that it is a protein that also has phosphatase activity. It is described that phospholipase C produced by Sarakuko and Aspergillus cytoii has a very high degradation activity of 2-hexadecanylamino 4-trophenylphosphorylcholine (see Non-Patent Document 7). Therefore, it is inferred that the enzyme is a protein that also has the ability to hydrolyze phosphodiesters other than phospholipids. Therefore, food processed using these enzymes may be unnecessarily modified.
- phospholipase C which has been known in the past, has problems such as insufficient strength or safety as an enzyme characteristic, and is distributed as phospholipase C to the market. So, there is no enzyme agent to date. Desirably, the properties of the enzyme agent are derived from microorganisms that have already produced food enzyme products, and have the ability to efficiently hydrolyze various phospholipids on the acidic side and in the vicinity of neutrality. In other words, it is active in a citrate buffer solution and is thermally stable to some extent. Furthermore, phospholipase C having a property that does not hydrolyze phosphate esters other than phospholipids as typified by glycerin phosphorylcholine.
- desirable phospholipase C properties include various phospholipids on the acidic side. However, it has the ability to efficiently hydrolyze even in the vicinity of neutrality, has activity in citrate buffer so that it can be used in the oil industry, and is thermally stable to some extent. Furthermore, it can be mentioned that it is a phospholipase c having a property of not hydrolyzing a phosphate ester other than phospholipid, as represented by glyce mouth phosphorylcholine.
- it is a phospholipase C derived from a microorganism that has already produced a food enzyme preparation.
- the present inventors are excellent in safety, have the ability to efficiently hydrolyze various phospholipids on the acidic side or near neutrality, have activity in citrate buffer, and are thermally stable to some extent.
- phospholipase C that does not hydrolyze phosphates other than phospholipids
- phospholipase derived from Aspergillus oryzae FERM ABP-10200 strain or NBRC 4190 strain, or Aspergillus tamari IAM 13907 strain C was purified and the phospholipase C gene derived from Aspergillus oryzae NBRC 4190 strain was cloned to complete the present invention.
- the present invention relates to (1) a phospholipase that exhibits activity at an acidic to neutral pH and does not substantially hydrolyze phosphate esters other than phospholipids.
- the phospholipase according to (6) produced by Aspergillus oryzae or Aspergillus tamarii (8)
- the host lipase according to (7) produced by Aspergillus oryzae FERM ABP-10200 strain or NBRC 4190 strain, or Aspergillus tamari IAM 13907 strain.
- Temperature stability is stable at a temperature of 45 ° C or lower at pH 4.5;
- pH stability is stable in the range of pH 3 to pHIO.
- Phospholipase which is a protein according to any one of the above.
- DNA encoding a protein having the amino acid sequence ability described in SEQ ID NO: 5; d) DNA comprising the nucleotide sequence of the coding region (CDS) of SEQ ID NO: 4! The DNA according to any one of the above.
- a process for producing phospholipase C comprising:
- FIG. 1 is a diagram showing the relationship between the activity of purified phospholipase C derived from Aspergillus oryzae FERM ABP-10200 strain and pH.
- FIG. 2 is a graph showing the relationship between the activity and temperature of purified phospholipase C derived from Aspergillus oryzae FERM ABP-10200 strain.
- FIG. 4 is a view showing the pH stability of purified phospholipase C derived from Aspergillus oryzae FERM ABP-10200 strain.
- FIG. 5 is a diagram showing the relationship between pH and activity of purified phospholipase C derived from Aspergillus tamari IAM 13907 strain.
- FIG. 6 is a graph showing the relationship between the activity and temperature of purified phospholipase C derived from Aspergillus tamari IAM 13907 strain.
- FIG. 7 is a view showing temperature stability of purified phospholipase C derived from Aspergillus tamari IAM 13907 strain.
- 'It is a figure showing sex.
- FIG. 9 is a graph showing the relationship between the activity and pH of purified phospholipase C derived from Aspergillus oryzae NBRC 4190 strain.
- the present invention is phospholipase C that is active at acidic to neutral pH and does not substantially hydrolyze phosphoesters other than phospholipids, or at acidic to neutral pH. It is a phospholipase that exhibits activity and does not have phosphatase activity.
- the phrase "does not substantially hydrolyze phosphate esters other than phospholipids” preferably means that the hydrolysis activity with respect to phosphatidylcholine (derived from egg yolk) is 100%, 30% or less for phosphatidic acid, more preferably 25% or less, and 15% or less for Z or glycephosphorylcholine, more preferably 10% or less, and Z or It means 10% or less, and more preferably 5% or less, with respect to para-trifluorophosphate.
- substantially does not hydrolyze glycephoryl phosphorylcholine and noranitrophenol phosphate is substantially does not hydrolyze glycephoryl phosphorylcholine and noranitrophenol phosphate.
- phosphatidic acid is recognized as a synthetic intermediate of neutral fat and glyceport phospholipid, it is not included in glyceport phospholipid (phospholipid) in the specification of the present application.
- “No phosphatase activity! /” Means that the degradation activity of phosphatidic acid or para-trophyl phosphate is 50% or less of the degradation activity of phosphatidylcholine.
- the activity is preferably 40% or less, more preferably 30% or less, and most preferably 25% or less of the phosphatidylcholine degradation activity.
- the degradation activity of paranitrophenol phosphate is preferably 30% or less, more preferably 20% or less, and most preferably 10% or less of the degradation activity of phosphatidylcholine.
- the phospholipase C of the present invention has a degrading activity for sphingomyelin, and preferably has a degrading activity for phosphatidylcholine or higher than that. Specifically, assuming that the degradation activity for phosphatidylcholine (derived from egg yolk) is 100%, the degradation activity for phosphatidylcholine is preferably 90% or more, more preferably 105% or more, and most preferably 115% or more. .
- the phospholipase C of the present invention has a decomposing activity for phosphatidylethanolamine, and preferably its decomposing activity is the same as that for phosphatidylcholine. Specifically, when the degradation activity for phosphatidylcholine (derived from egg yolk) is 100%, the degradation activity for phosphatidylethanolamine is preferably 80% or more, more preferably 85% or more, most preferably 90% or more, Less than 150%.
- Phospholipase C is not phosphatidylinositol-specific! /, Meaning that the degradation activity of substrates other than phosphatidylinositol is higher than the degradation activity (relative activity) of phosphatidylinositol.
- the substrate other than phosphatidylinositol is preferably phosphatidylcholine, phosphatidylethanolamine, phosphatidylinositol or phosphatidylglycerol.
- the optimum pH of the phospholipase C of the present invention is preferably in the range of acidic to neutral pH, more preferably in the range of pH 3 to pH 6, and further preferably in the range of pH 3 to pH 5. Range, most preferably in the range of pH 4 to pH 5.
- the phospholipase C of the present invention has a relative activity at pH 7 of preferably 20% or less. More preferably, it is 40% or more, most preferably 50% or more.
- the optimum temperature of the phospholipase C of the present invention is preferably in the range of 45 ° C to 70 ° C, and more preferably in the range of 55 ° C to 70 ° C. Most preferably, it is in the range of 60 ° C to 70 ° C.
- the phospholipase C of the present invention preferably has a relative activity of 50% or more in the range of 55 ° C to 70 ° C, more preferably 50% in the range of 45 ° C to 70 ° C.
- the relative activity is most preferably 50% in the range of 35 ° C to 70 ° C.
- the relative activity is preferably 80% or more.
- stable means having 40% or more residual hydrolysis activity
- the phospholipase C of the present invention is 45 ° C.
- the residual activity is preferably 50% or more, more preferably 70% or more, and most preferably 80% or more.
- the phospholipase C of the present invention has a residual hydrolysis activity of 40% or more at a treatment temperature of preferably 45 ° C., more preferably 50 ° C., and most preferably 60 ° C.
- stable means that it has a residual hydrolysis activity of 5% or more after storage treatment, and the phospholipase C of the present invention is treated.
- the residual hydrolytic activity is preferably 0% or more, more preferably 50% or more, and most preferably 60% or more.
- the treatment pH is in the range of pH 6 to pH 8
- the residual hydrolysis activity is preferably 60% or more, more preferably 70% or more, and most preferably 80% or more.
- phospholipase C of the present invention includes any one of the amino acid sequences shown in SEQ ID NOs: 1, 2 and 3, preferably two, most preferably all three. And a protein having phospholipase C activity. When the protein contains two or more of these three amino acid sequences, the order of each amino acid sequence may be in any order! /.
- the protein having the amino acid sequence ability of SEQ ID NO: 5 is characterized by having an amino acid sequence ability in which one or several amino acids are deleted, substituted or added, and having phospholipase C activity.
- Such proteins are also included in the present invention.
- Substituted amino acid sequence For example, a protein obtained by substituting a nucleotide sequence corresponding to cysteine of the interleukin 2 (IL-2) gene with a nucleotide sequence corresponding to serine. Is known to retain IL-2 activity (Wang, A. et al. (1984) Science 224, 1431-1433).
- Another example of the phospholipase C of the present invention includes a protein comprising the amino acid sequence of SEQ ID NO: 5.
- a protein comprising the amino acid sequence set forth in SEQ ID NO: 5 is included in the present invention as long as it has phospholipase C activity.
- phospholipase C of the present invention is a protein consisting of the amino acid sequence of SEQ ID NO: 5 and modified with a sugar chain.
- a protein comprising such a protein is also included in the present invention as long as it has phospholipase C activity.
- the “DNA of the present invention” refers to DNA encoding the phospholipase C of the present invention.
- the DNA can be in any form as far as it is known, including cDNA, genomic DNA, artificially modified DNA, and chemically synthesized DNA.
- DNA of the present invention examples include DNA that is the nucleotide sequence of the coding region (CDS) of SEQ ID NO: 4 and encodes a protein having phospholipase C activity.
- CDS coding region
- DNA of the present invention includes DNA having a nucleotide sequence homology of 70% or more with the nucleotide sequence of the coding region (CDS) of SEQ ID NO: 4.
- CDS coding region
- nucleotide of the present invention is DNA encoding a protein comprising the amino acid sequence set forth in SEQ ID NO: 4.
- the codon corresponding to the desired amino acid can be selected arbitrarily and can be determined according to a conventional method in consideration of, for example, the codon usage frequency of the host to be used. (Grantham, R. et al. (1981) Nucleic Acids Res. 9, 14 3-174) o
- partial modification of the codons of these nucleotide sequences can be carried out in accordance with a conventional method from a synthetic oligonucleotide encoding the desired modification.
- Site-specific mutagenesis / Mark, DF et al. (1984) Proc. Natl. Acad. Sci. USA 81, 5662-5666, etc. can be used.
- DNA of the present invention includes a DNA consisting of the nucleotide sequence of the coding region (CDS) of SEQ ID NO: 4. Further, DNA containing the nucleotide sequence of the coding region (CDS) of SEQ ID NO: 4 is also included in the present invention as long as it encodes a protein having phospholipase C activity.
- Examples of the phospholipase C of the present invention include a protein comprising an amino acid sequence encoded by the DNA of the present invention.
- a method of cutting DNA from the end using exonuclease Bal31 or the like Kerat Toshimitsu et al., "Sequence of Biochemistry Experiment 1, Gene Research Method ⁇ " 335-354), cassette mutation method (Toshimitsu Kishimoto, "New Chemistry Experiment 2, Nucleic Acid III Recombinant DNA Technology” 242-251) .
- proteins obtained by genetic engineering techniques based on the DNA of the present invention are included in the present invention as long as they have phospholipase C activity.
- a phospholipase is not necessarily required to have all of the amino acid sequence described in SEQ ID NO: 5, for example, even a protein having a partial sequence ability, as long as the protein exhibits phospholipase C activity.
- phospholipase C is also included in the present invention.
- Phospholipase C used in the present invention may be a product obtained by purifying phospholipase C-producing bacteria, a crude product, a cell disruption solution, or a cell culture supernatant as it is.
- a surfactant in addition to a carbon source and a nitrogen source in the medium.
- it is preferably cultured in a medium of natural materials such as fish meal, sorghum and cottonseed meal.
- the surfactant include triton, tween, sucrose fatty acid ester, sodium cholate, sodium deoxycholate and saponin.
- Phospholipase C-producing bacteria can be cultured using an ordinary culture apparatus and medium.
- methods such as liquid culture and solid culture can be appropriately selected.
- liquid culture flask culture or culture using a fermenter can be performed. After the start of culture, the medium is not added.
- Carbon and nitrogen sources can be added to the medium, and vitamins and trace metals can be added as necessary.
- the carbon source include monosaccharides such as glucose, mannose, galactose, and phenolate, disaccharides such as manoleose, cellobiose, isomanoleose, ratatose, and sucrose, polysaccharides such as starch, and maltoeduct.
- inorganic nitrogen such as ammonia, ammonium sulfate and ammonium nitrate
- organic nitrogen such as first-stratate, malto-stratate, corn steep liquor and peptone
- the amount of the composition in these media can be appropriately selected.
- the culture temperature, pH, and aeration amount can be appropriately selected so as to be suitable for phospholipase C production.
- Centrifugation is carried out after the cultivation of the phospholipase C-producing bacteria to remove the bacterial cells, and the cultured supernatant can be used as it is as a crude enzyme solution.
- a crude enzyme solution can be roughly purified by ion exchange chromatography or the like, or purified.
- Aspergillus oryzae FERM ABP-10200 strain or NBRC 4 190 strain or Aspergillus tamari IAM 13907 referred to in the present invention are all mutant strains as long as they can produce phospholipase C of the present invention. Is included. These mutant strains also include those obtained by genetic methods such as recombination, transduction, and transformation. That is, Aspergillus oryzae FERM ABP-10200 or NBRC 4190 strain or Aspergillus tamari IAM 13907 strain, mutants thereof and strains that are not clearly distinguished from them are those that produce the phospholipase C of the present invention. All Aspergillus oryzae FERM ABP—10200 or NBRC 4190 shares V ⁇ are included in Aspergillus tamari IAM 13907.
- the phospholipase C of the present invention can also be obtained from a culture product of a transformed cell obtained by transforming a host cell with a recombinant plasmid in which the DNA of the present invention is inserted into a vector.
- a recombinant plasmid in which the DNA of the present invention is inserted into an appropriate vector is also included in the present invention.
- a vector used for such a purpose various commonly known vectors can be used. Suitable examples include, but are not limited to, a vector for prokaryotic cells, a vector for eukaryotic cells, a vector for mammalian cells and the like.
- Such recombinant plasmids can transform other prokaryotic or eukaryotic host cells. Furthermore, the ability to use a vector having an appropriate promoter sequence and Z or a sequence involved in phenotypic expression, or by introducing such a sequence, the gene can be expressed in each host. Is possible.
- Such an expression vector is a preferred embodiment of the recombinant plasmid of the present invention.
- Host cells can be obtained by introducing the recombinant plasmid of the present invention into various cells. These cells can be either prokaryotic cells or eukaryotic cells as long as they can introduce plasmids! /.
- Examples of the prokaryotic host include Escherichia coli and Bacillus subtilis.
- the host cells are transformed with a plasmid vector containing a rebricon derived from a species compatible with the host, ie, an origin of replication, and regulatory sequences.
- a vector having a sequence capable of imparting phenotypic (phenotypic) selectivity to transformed cells is preferred.
- the K12 strain is often used as E. coli, and the vector is generally limited to the ability to use pBR 322 or pUC plasmids.
- Various known strains and vectors can be used. it can.
- trp tryptophan
- lac lactose
- tac tryptophan 'latatose
- lipoprotein (1 pp) promoter lipoprotein (1 pp) promoter
- Tu polypeptide chain elongation factor Tu (tuffi) promoter and the like, and any promoter can be used for production of the phospholipase c of the present invention.
- pTUB228 (Ohmu ra, K. et al. (1984) J. Biochem. 95, 87-93) is used as a preferred vector for Bacillus subtilis. It is not limited to.
- Secretion expression outside the cell can also be achieved by linking a DNA sequence encoding the signal peptide sequence of Bacillus subtilis at amylase as the promoter.
- the host cells of eukaryotic cells include cells of vertebrates, insects, yeasts, etc., and vertebrate cells include cells derived from mammals, for example, COS cells (Gluzman, Y. (1981) Cell 23, 175-182, ATCC CRL— 1650) and Chinese'no, Muster ovary cells (CHO cells, ATCC CCL-61) dihydrofolate reductase deficient strains (Urlaub, G. and Chasin, LA) (1980) Proc. Natl. Acad. Sci. USA 77, 4126-4220) and the like can be used.
- COS cells Gluzman, Y. (1981) Cell 23, 175-182, ATCC CRL— 1650
- Chinese'no, Muster ovary cells CHO cells, ATCC CCL-61) dihydrofolate reductase deficient strains (Urlaub, G. and Chasin, LA) (1980) Proc. Natl. Acad. Sci. USA 77, 4126-4220) and
- an expression promoter for vertebrate cells a promoter that is usually located upstream of a gene to be expressed, an RNA splice site, a polyadenylation site, a transcription termination sequence, and the like can be used. In addition, this may have a replication origin if necessary.
- the expression vector include pSV2dhfr (Subramani, S. et al. (1981) Mol. Cell. Biol. 1, 854-864) having the SV40 early promoter. It is not limited to.
- the expression vector has an SV40 replication origin, and can self-propagate in COS cells. Furthermore, a transcription promoter, transcription termination signal , And those with RNA splice sites can be used.
- the expression vector is obtained by the following method: Jetylaminoethyl (DEAE) -dextran method (Luth man, H. and Magnusson, G. (1983) Nucleic Acids Res, 11, 1295-1308) (Graham, FL and van der Eb, AJ (1973) Virology 52, 4 56-457), and electric pulse perforation (Neumann, E. et al. (1982) EMBO J.
- vectors capable of expressing the neo gene that functions as an antibiotic G418 resistance marker such as pRSVneo (Sambrook, J. et al. (1989): “Molecular Cloning A Laboratory Manual ⁇ Cold Spring Harbor Laboratory, NY) and pSV2— neo (Southern, PJ and Berg, P. (1982) J. Mol. Appl. Genet. 1, 327-341), etc. are cotransfected to select G418-resistant colonies, whereby the phospholipase of the present invention is selected. A transformed cell that stably produces C can be obtained.
- an insect cell When an insect cell is used as a host cell, an ovarian cell-derived cell line of Spodoptera frugiperd a (Sf-9 or Sf-21) of Lepidoptera, or a Hygh Five cell derived from an egg cell of Trichoplusia ni (Wickham) , TJ et al, (1992) Biotechnol. Prog. I: 391-396) are often used as host cells, and the baculovirus transfer vector is the promoter of the autographer nuclear polyhedrosis virus (AcNPV) polyhedrin protein. P VL1392Z1393 is used vigorously (Kidd, IM and VC Emery (1993) The use of baculoviruses as expression vectors.
- vectors using baculovirus P10 and promoters of the same basic protein can also be used.
- a recombinant protein as a secreted protein by linking the secretory signal sequence of the envelope surface protein GP67 of AcNPV to the N-terminal side of the target protein (Zhe-mei Wang, et al. (19 98) Biol. Chem., 379, 167-174).
- yeast As an expression system using a eukaryotic microorganism as a host cell, yeast is generally well known, and among them, Saccharomyces yeasts such as baker's yeast Saccharomyces cerevisiae and petroleum yeast Pichia pastoris are preferable.
- expression vectors for eukaryotic microorganisms such as yeast include, for example, the promoter of the anoleconole dehydrogenase gene (Bennetzen, J. and Hall, BD (1982) J. Biol. Chem. 257, 3018-3025) and acid.
- a phosphatase gene promoter (Miyanohara, A. et al. (1983) Proc. Natl. Acad. Sci.
- the transformant obtained as described above can be cultured according to a conventional method, and the phospholipase C of the present invention is produced intracellularly or extracellularly by the culture.
- the medium used for the culture various kinds of commonly used media can be selected depending on the host cells employed.
- the above-mentioned COS cells can be RPMI 1640 medium or Dulbecco's modified Eagle medium (hereinafter “DMEM”). "T, u)" and other medium supplemented with serum components such as urine fetal serum as needed can be used.
- DMEM Dulbecco's modified Eagle medium
- T, u Dulbecco's modified Eagle medium
- serum components such as urine fetal serum as needed
- the CO concentration is in the range of 0 to 50%.
- the range is preferably 1 to 10%, more preferably 5%.
- the culture temperature is preferably 0 to 99 ° C, more preferably 20 to 50 ° C, and more preferably 35 to 40 ° C.
- the phospholipase C of the present invention which is produced as a thread and exchange protein in or outside the transformant by the above-described culture, is obtained from the cultured product from the physical properties, chemical properties, Various separation operations using biochemical properties (enzyme activity, etc.) ("Biochemical Data Book II", 1175-1259, 1st edition, 1st print, June 23, 1980 Tokyo i Issued by the same person; see Biochemistry, vol. 25, No. 25, p8274-8277 (1986); Eur. J. Biochem., 163, p313-321 (1987), etc.).
- the method include normal reconstitution treatment, treatment with a protein precipitating agent (salting out method), centrifugation, osmotic shock method, freeze-thaw method, ultrasonic disruption, ultrafiltration, gel filtration.
- a protein precipitating agent salting out method
- centrifugation osmotic shock method
- freeze-thaw method ultrasonic disruption
- ultrafiltration gel filtration.
- various liquid chromatography such as adsorption chromatography, ion exchange chromatography, affinity chromatography, high performance liquid chromatography (HPLC), dialysis method, and combinations thereof.
- HPLC high performance liquid chromatography
- a desired recombinant protein can be produced on an industrial scale in a high yield.
- histidine having 6 residues to the recombinant protein to be expressed, it can be efficiently purified on a nickel-affinity column.
- the phospholipase C of the present invention can be easily produced in large quantities with high yield and high purity.
- Phospholipase C produced by the method as described above can also be mentioned as a preferred example of the present invention.
- the phospholipase C-producing bacterium refers to a microorganism substantially having a phospholipase C-producing ability, and includes a microorganism that accumulates phospholipase C in the microbial cell, a microorganism that secretes it outside the microbial cell, and the like.
- phospholipase C purified from culture supernatant or culture supernatant of phospholipase C-producing bacteria bacteria that secrete phospholipase C outside the cells can be used.
- Aspergillus oryzae or Aspergillus' Tamari-derived phospholipase C can be used, and more preferably, Aspergillus oryzae FERM ABP-10200 strain or NBRC Phospholipase C derived from strain 4190 or Aspergillus tamari IAM 13907 can be used.
- Phospholipase C may be produced by these phospholipase C-producing bacteria themselves, or may be produced by a mutant or a modified product thereof, and a gene encoding phospholipase C of these phospholipase C-producing bacteria. It may be a recombinant protein produced from a transformant obtained by introducing into a host! / ⁇ .
- Aspergillus oryzae NBRC 4190 is an independent administrative agency, Product Evaluation Technology Infrastructure Organization, Biotechnology Headquarters, Biological Resource Center (NBRC) 292– 0818 Kisarazu Kazusa Kamashisa, Chiba Prefecture, Japan 292— 0818, Home page address (http://www.nite.go.jp/>).
- IAM 13907 strain is the IAM institute of Molecular and Cellular Biosciences, The University of Tokyo; 1-1, Yayoi, Bunkyo-ku, Tokyo 113-0032, Manpower from the home page address ⁇ htt p: //www.iam.u—tokyo.ac.jp/indexe.html>).
- Aspergillus oryzae FERM ABP Aspergillus oryzae FERM ABP—according to the clicked literature (Klich, MA (002) Identmcation of common Aspergillus and entraalbureau voor Schimmelcultures, Ut recht, The Netherlands), 4 types of media (CYA media, CY20S media, CZ cultivation Ground, MEA medium) and inoculated mycological properties.
- composition of the four types of media is as follows.
- CYA medium Czapek Yeast Extract Agar medium
- Zapec concentrate (NaNO 30g, KC1 5g, MgSO ⁇ 7 ⁇ O 5g, FeSO-7H O
- CY20S medium [20% Czapek Yeast Extrac t Agar with 20% Sucrose medium]
- CZ medium [Czapek Dox Agar medium]
- Colonies in CYA medium are 36-40 mm in diameter for 1 week of culture at 25 ° C.
- the mouth is a little thicker wool, fluffy at the center, and forms radial grooves from the center.
- the mycelium is white.
- Conidia are sparsely formed in the center, and grayish yellow (4B4) force is also yellowish white (4A2). No exudate or sclerotia is observed.
- the back side is pale yellow (2A4) to white (2A1), and radial grooves are formed from the center. No soluble pigment is observed.
- Colonies in CYA medium are 54-58 mm in diameter at 37 ° C for 1 week. One is thick and woolly. The mycelium is white.
- the conidia are formed in the center and have grayish yellow (4B4) force yellowish white (4A2). No exudate or sclerotia is observed.
- the back side is pale orange (4A4) to white (4A2), and radial grooves are formed from the center. No soluble pigment is observed.
- Colonies in CY20S medium have a diameter of 35-41 mm when cultured for 1 week at 25 ° C.
- the colony properties are similar to those of CYA medium, but there are a little more fluffy hyphae in the center.
- Colonies in CZ medium have a diameter of 17-21 mm when cultured for 1 week at 25 ° C. Colony properties are the same as CYA medium. Colonies have small formation of conidia.
- Colonies in MEA medium are 37-4 lmm in diameter at 25 ° C for 1 week. The mouth is thin and fluffy. The mycelium is white. Conidia are sparsely formed in the center, and are dark green (26D4) to grayish green (26D6). No exudate or sclerotia is observed. The back side is gray yellow (4B3) force yellowish white (4A2), and no soluble pigment is observed!
- the conidia head has a loose cylindrical shape with a radial force.
- the conidia pattern has a width of 6.7-13.6 / z m, a length of 3 02. 2-1398. O ⁇ m, colorless and rough.
- the apical sac is a sub-spherical force-flask shape with a width of 14.6-29.3 ⁇ m.
- Aspergilla is mainly single row (uniseriate) and rarely double row (bi seriate).
- Metre or phialide also creates the upper half force of the apical sac.
- the metre is 1 1. 3-28. 3 X 5. 2-9. 9 m.
- the phialide is in the form of a flask, 8.4—21.3 X 3. 8-7.
- Conidia are smooth, subspherical to oval, diameter 4.2-6.3 m
- Phospholipase C produced and purified by Aspergillus oryzae FERM ABP-10200 strain or NBRC 4190 strain or Aspergillus tamari IAM 13907 strain has the following properties.
- the hydrolytic activity described in 4) is in the range of 0 ° C to 80 ° C.
- Table 1 shows the relative activity when the activity against egg yolk-derived phosphatidylcholine is defined as 100%.
- the egg yolk-derived substrate and soybean-derived substrate are described as such.
- egg yolk-derived lecithin was purchased from Nacalai Testa Co., Ltd.
- soybean-derived lecithin was purchased from Sakai Oil Co., Ltd.
- other substrates were purchased from Sigma Aldrich Japan Co., Ltd.
- Phosphatidylhetanoylamine (from egg yolk) 1 0 1
- Lecithin (derived from egg yolk) 8 8
- Lysophosphatidylcholine (derived from egg yolk) 4 1
- Phosphatidylcholine (derived from soybean) 9 4
- Phosphatidylhetanoylamine (derived from soybean) 9 0
- Lecithin (derived from soybean) 8 2
- Sphingomyelin (derived from bovine brain) 1 2 1
- Sphingomyelin (derived from egg yolk) 1 2 5
- the protein is modified with a sugar chain.
- the properties of the phospholipase C of the present invention include the following, but are not limited thereto.
- the hydrolytic activity described in 4) is in the range of 0 ° C to 80 ° C.
- the present invention also includes a method for producing the phospholipase C of the present invention.
- Phospholipase C can be produced by culturing phospholipase C-producing microorganisms such as Aspergillus oryzae FERM ABP-10200 strain, NBRC 4190 strain or Aspergillus tamari IAM 13907 strain in a medium.
- the hydrolysis activity of phospholipase C was measured as follows.
- Egg yolk lecithin (Nacalai Testa Co., Ltd.) 1.5% of 4% (wt / v) TritonX—100
- 60 ⁇ l of 200 mM acetate buffer (pH 5.5) to 60 ⁇ l of substrate solution dissolved in 50 ml
- the temperature was kept at 37 ° C.
- the mixture solution was stirred uniformly with the enzyme solution 601, and incubated at 37 ° C for 3 hours to carry out the enzyme reaction.
- the phosphoryl base resulting from the enzymatic reaction was hydrolyzed with alkaline phosphatase.
- ⁇ 1> Add 200 mM Tris' hydrochloric acid buffer (pH 8.0) 50 1 and alkaline phosphatase (Sigma Aldrich Japan) 1 ⁇ 1 to the enzyme reaction solution 1 prepared in ⁇ 1> for 40 minutes at 37 ° C. I did it. At this time, a sample was prepared at the same time without using alkaline phosphatase as a blank.
- 1,200 ml of the crude enzyme solution obtained in 1) was dialyzed 8 times for 12 hours against 10 mM Tris' hydrochloric acid buffer (pH 7.5) 8, OOOml. This was added to a DEAE Toyopearl (Tosohichi Co., Ltd.) column (diameter 2.2 cm X length 20 cm) previously equilibrated with 10 mM Tris' hydrochloric acid buffer (pH 7.5) and adsorbed. After thoroughly washing the column with 10 mM Tris 'hydrochloric acid buffer (pH 7.5), create a linear concentration gradient of 0 to 0.2 M sodium chloride in 600 ml of 10 mM Tris' hydrochloric acid buffer (pH 7.5).
- the egg yolk-derived lecithin-degrading activity was eluted in the fraction (90 ml) having a sodium chloride concentration of 0.05M to 0.08M. This was used as a crudely purified enzyme fraction.
- This fraction was used as a purified enzyme solution.
- the molecular weight of the purified enzyme was determined by SDS-PAGE electrophoresis using 5% polyacrylamide gel (see Laemmli, UK, Nature, 227, 680 (1970)). The following were used as standard proteins: a. Phosphorylase, molecular weight 94, 000: b. Albumin, molecular weight 67, 000: c. Ovalbumin, molecular weight 43, 000: d .Carbonic 'carbonic anhydrase, molecular weight 30,000: e. Trypsin' Inhibitor (trypsin inhibitor), molecular weight 20, 100: f. ⁇ -Latatalbumin (a-lactalbumin), molecular weight 14,400.
- the purified enzyme showed a single band with a molecular weight of about 87,000.
- a 500 ml Erlenmeyer flask (seed flask) containing 100 ml of the medium shown in Table 2 is inoculated with 1 ml of filter-sterilized 5% sodium deoxycholate solution and Aspergillus tamari IAM 13907 strain at 26 ° C. Incubated at 170 rpm for 5 days. After completion of the culture, centrifugation was performed at 4 ° C, 10,000 X G for 10 minutes. The obtained supernatant was used as a crude enzyme solution.
- Example 1 Purification was carried out in the same manner as in 3) to obtain a purified enzyme solution.
- Example 1.4 Measurement was performed in the same manner as in 4).
- the purified enzyme showed a single band with a molecular weight of about 87,000.
- HiLoad Sephadex200pg (Amersham Bioscience Co., Ltd.) obtained by concentrating 35 ml of the obtained active fraction and equilibrating in advance with 10 mM Tris' hydrochloric acid buffer (PH7.5) containing 0.15 M sodium chloride After loading on a column (diameter 16 mm ⁇ 60 cm), elution was performed with 1 OmM Tris' hydrochloric acid buffer (pH 7.5) containing 0.15 M sodium chloride. Egg yolk-derived lecithin-degrading activity was eluted in fractions with an elution volume of 60 to 70 ml.
- This fraction was used as a purified enzyme solution.
- the purified enzyme showed a single band with a molecular weight of about 87,000.
- Example 4 Determination of partial amino acid sequence of phospholipase C from Aspergillus oryzae NBRC 4190 strain
- the purified enzyme solution was concentrated to about 1 mg / ml using an ultrafiltration membrane (Sartorius VIVASPIN2, molecular weight fraction 10,000).
- RNA Aspergillus oryzae NBRC 4190 strain was precultured in liquid medium (2% polypeptone, 0.5% yeast estratate, 0.02% hydrogen phosphate 2 potassium, 0.05% magnesium sulfate) 2 Oml at 26 ° C for 1 day . Thereafter, 1% inoculation was carried out in a liquid medium (5% fish meal) and cultured at 26 ° C for 4 days. The cultured cells were collected by aspiration and transferred to a mortar (autoclaved) at -80 ° C. While adding liquid nitrogen, the cells were crushed with a pestle to form a powder. The whole ribonucleic acid was purified from the completely powdered cells using RNeasy Plant Mini Kit (Qiagen Co., Ltd.). A solution force of 50 1 with a concentration of 905 ng / 1 was obtained.
- the gene sequence was decoded by 5'RACE method and 3'RACE method. Specifically, PCR was performed using Ex Taq TM (Takara Bio Inc.) as a polymerase using 5'RACE System and 3'RACE System (both Invitrogen Corp.). The PCR primers used at this time were 5'-GGCCACGCGTCGAC TAGTAC-3 'and 5'-GACAGTGTAGTCGAGCACAGCGAA-3' for 5 'gene sequence amplification, and 5'-GACTCTGCCACCGCAATCGGCTA- for 3' gene sequence amplification. 3 'and 5'- GGCCACGCGTC GACTAGTAC-3' were used.
- the PCR cycle was amplified at 94 ° C for 5 minutes, (94 ° C for 30 seconds, 55 ° C-30 seconds, 72 'for 2 minutes 30 seconds), 30 ° C for 10 minutes at 4 ° C.
- a DNA having a length of about 12 OOb.p. on the 5 ′ side and about 800 b.p. on the 3 ′ side was amplified.
- Each PCR product was subjected to agarose gel electrophoresis and then purified with a QIAquick Gel Extraction Kit (Qiagen Co., Ltd.).
- the purified product was ligated to a vector using TOPO TM TA Cloning Kit (Invitrogen Corp.) and transformed. After culturing the transformed E. coli on an agar medium (LB / Agar (Wako Pure Chemical Industries, Ltd.) overnight at 37 ° C, the grown colonies were grown at 37 ° C overnight in a liquid medium (LBbroth ( Wako Pure Chemical Industries, Ltd.)).
- LBbroth Wako Pure Chemical Industries, Ltd.
- coli plasmid was purified using QIAprep Spin Miniprep Kit (Qiagen Co., Ltd.) and subjected to DNA sequence analysis.
- the result of DNA sequence analysis is shown in SEQ ID NO: 4.
- the amino acid sequence deduced from the DNA sequence is shown in SEQ ID NO: 5.
- Example 6 Glycopeptidase treatment of phospholipase C from Aspergillus oryzae NBRC 4190 strain
- Test Example 1 Aspergillus oryzae FERM ABP— Properties of purified enzyme solution of phospholipase C derived from 10200 strain
- the activity of the purified enzyme solution obtained in 3) of Example 1 was measured.
- Example 2 The method shown in 2) of Example 1 was used. However, the enzyme reaction time was set at 37 ° C for 10 minutes.
- the following buffers were used: pH 2.3 to pH 3.7, glycine monohydrochloride buffer: pH 3.3 to pH 6.2, citrate monosodium citrate buffer: pH 6.1 NO To pH8.0, MOPS buffer: At pH 8.2 to pH 9.2, Atkins—Pantin buffer.
- the hydrolytic activity under the pH condition with the highest activity is defined as 100%, and the hydrolytic activity of the enzyme at each pH is shown as a relative value in FIG. The optimum pH was around pH 4.5 in citrate buffer.
- the temperature activity in citrate buffer PH4.5 was measured.
- the measurement method was based on the method shown in 2) of Example 1. However, the enzyme reaction time was set at 37 ° C for 20 minutes.
- the hydrolysis activity under the temperature condition with the highest activity was taken as 100%, and the hydrolysis activity of the enzyme at each temperature is shown as a relative value in FIG.
- the optimum temperature was around 65 ° C.
- the purified enzyme solution was treated at various temperatures for 30 minutes, and the residual hydrolysis activity was measured.
- 25 mM citrate buffer (pH 4.5) 90 / zl previously maintained at the treatment temperature
- Enzyme solution 10 was added and stirred until uniform, and kept warm for 30 minutes.
- 60 ⁇ l of egg yolk lecithin solution prepared in Example 1 60 ⁇ l of 200 mM citrate buffer solution (pH 4.5) was kept at 37 ° C., and the enzyme solution 60 / zl heated was added.
- the enzyme reaction was performed at 37 ° C for 30 minutes.
- the free phosphoryl base was quantified according to 2) of Example 1.
- the highest residual hydrolysis activity was taken as 100%, and the hydrolysis activity at each temperature was summarized as a relative value in FIG. It was stable at a temperature of at least 60 ° C at pH 4.5.
- Example 1 60 1 of the solution was added and stirred to homogenize, and the enzyme reaction was performed at 37 ° C for 10 minutes.
- the quantification of the free phosphoryl base was in accordance with 2) of Example 1.
- the highest residual hydrolysis activity is taken as 100%, and the hydrolysis activity at each pH is shown as a relative value in FIG. It was stable in the range of pH 3 to pHIO.
- Phosphatidylhetanoylamine (from egg yolk) 1 0 1
- Lecithin (derived from egg yolk) 8 8
- Lysophosphatidylcholine (derived from egg yolk) 4 1
- Phosphatidylcholine (derived from soybean) 9 4
- Phosphatidylhetanoylamine (derived from soybean) 9 0
- Lecithin (derived from soybean) 8 2
- Sphingomyelin (derived from bovine brain) 1 2 1
- Sphingomyelin (derived from egg yolk) 1 2 5
- the activity was measured using the purified enzyme solution obtained in 2) of Example 2.
- Test Example According to the method shown in 1.
- the hydrolysis activity under the pH conditions with the highest activity was defined as 100%, and the enzyme hydrolysis activity at each pH is shown in FIG. 5 as relative values.
- the optimum pH was around pH 4.5.
- FIG. 6 shows the hydrolysis activity under the temperature conditions with the highest activity as 100% and the hydrolysis activity of the enzyme at each temperature as a relative value.
- the optimum temperature was around 65 ° C. [0148] 3) Temperature stability
- Test Example According to the method shown in 1. The highest residual hydrolysis activity is taken as 100%, and the hydrolysis activity at each temperature is shown as a relative value in FIG. It was stable at a temperature below 45 ° C at pH 4.5.
- Test Example According to the method shown in 1. The highest residual hydrolysis activity is taken as 100%, and the hydrolysis activity at each pH is shown as a relative value in FIG. It was stable in the range of pH 3 to pHIO.
- Table 5 shows the relative activities when the hydrolysis activity for egg yolk-derived phosphatidylcholine is defined as 100%.
- Phosphatidic acid (derived from egg yolk) 1 6
- Lecithin (derived from egg yolk) 9 1
- Lysophosphatidylcholine (derived from egg yolk) 5 3
- Glyce mouth phosphorylcholine (derived from soybean) 8
- Phosphatidylcholine (derived from soybean) 9 1
- Lecithin (derived from soybean) 7 5
- Test Example 3 Aspergillus oryzae Purified phospholipase C from NBRC4190 strain Activity was measured using the purified enzyme solution obtained in 2) of Example 3.
- Test Example According to the method shown in 1.
- the hydrolysis activity under the pH condition with the highest activity was defined as 100%, and the hydrolysis activity of the enzyme at each pH is shown as a relative value in FIG.
- the optimum pH was around pH 4.5.
- Test Example According to the method shown in 1. Table 6 shows the relative activity when the hydrolysis activity for egg yolk-derived phosphatidylcholine is defined as 100%. Relative activity (%) Substrate Phosphatidylcholine (derived from egg yolk) 1 0 0
- Phosphatidic acid (derived from egg yolk) 2 2
- Lecithin (derived from egg yolk) 8 9
- Lysophosphatidylcholine (derived from egg yolk) 4 6
- Lecithin (derived from soybean) 8 1
- the phospholipase C of the present invention is derived from Aspergillus oryzae FERM ABP-10200 strain or NBRC 4190 strain or Aspergillus tamari IAM 139 07 strain, which is excellent in safety and has various glyceport phospholipids on the acidic side. Has the ability to hydrolyze efficiently even in the vicinity of neutrality and has activity in citrate buffer. It is an enzyme that is thermally stable to the extent that it does not hydrolyze phosphate esters other than phospholipids, and has excellent effects in both the food industry and the oil industry.
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Botany (AREA)
- Mycology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Enzymes And Modification Thereof (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/JP2006/304710 WO2007105264A1 (ja) | 2006-03-10 | 2006-03-10 | 新規ホスホリパーゼc |
US12/224,867 US7993874B2 (en) | 2006-03-10 | 2006-03-10 | Phospholipase C enzyme(s) |
EP11164069.4A EP2368978B1 (en) | 2006-03-10 | 2006-03-10 | Novel phospholipase C enzyme(s) |
CN2006800537852A CN101410513B (zh) | 2006-03-10 | 2006-03-10 | 新型磷脂酶c |
EP06728878.7A EP1995313B1 (en) | 2006-03-10 | 2006-03-10 | Novel phospholipase c |
US13/134,964 US20110293786A1 (en) | 2006-03-10 | 2011-06-22 | Phospholipase C enzyme |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/JP2006/304710 WO2007105264A1 (ja) | 2006-03-10 | 2006-03-10 | 新規ホスホリパーゼc |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/134,964 Division US20110293786A1 (en) | 2006-03-10 | 2011-06-22 | Phospholipase C enzyme |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2007105264A1 true WO2007105264A1 (ja) | 2007-09-20 |
Family
ID=38509114
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2006/304710 WO2007105264A1 (ja) | 2006-03-10 | 2006-03-10 | 新規ホスホリパーゼc |
Country Status (4)
Country | Link |
---|---|
US (2) | US7993874B2 (ja) |
EP (2) | EP1995313B1 (ja) |
CN (1) | CN101410513B (ja) |
WO (1) | WO2007105264A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102960770A (zh) * | 2012-12-07 | 2013-03-13 | 北京二商健力食品科技有限公司 | 一种速溶蛋黄粉及其制备方法 |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR122020023911B1 (pt) | 2010-11-12 | 2022-02-15 | Novozymes A/S | Construto de ácido nucleico, célula microbiana hospedeira recombinante, e, método de produção do polipeptídeo |
WO2014090161A1 (en) * | 2012-12-11 | 2014-06-19 | Novozymes A/S | Polypeptides having phospholipase c activity and polynucleotides encoding same |
CN104630175B (zh) * | 2013-11-14 | 2019-10-25 | 丰益(上海)生物技术研发中心有限公司 | 一种磷脂酶c |
CN104694394B (zh) * | 2013-12-05 | 2019-07-12 | 丰益(上海)生物技术研发中心有限公司 | 一种枝孢霉表达的磷脂酶c及其产生菌株 |
CN110129299B (zh) * | 2016-06-02 | 2021-08-03 | 天津科技大学 | 磷脂酶d及其应用 |
CN110951621B (zh) * | 2019-11-18 | 2022-05-31 | 无锡优普克生物科技有限公司 | 一种产磷脂酶的黑曲霉菌株 |
CN114574281A (zh) * | 2021-12-06 | 2022-06-03 | 中粮营养健康研究院有限公司 | 一种浓香型风味油脂的酶法脱胶方法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2000166543A (ja) | 1998-12-04 | 2000-06-20 | Shin Nippon Kagaku Kogyo Kk | ホスホリパーゼc及びその製造法 |
WO2004104193A2 (en) * | 2003-05-24 | 2004-12-02 | F2G Ltd | Phospholipase c |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS531356B2 (ja) | 1972-10-07 | 1978-01-18 | ||
JPS5533308B2 (ja) | 1974-02-05 | 1980-08-29 | ||
DK1224267T3 (da) * | 1999-10-14 | 2011-04-26 | Novozymes As | Lysophospholipase |
DE10032058A1 (de) | 2000-07-05 | 2002-01-17 | Basf Ag | Mikrobielle Produktion von R-Phenylacetylcarbinol durch biologische Umwandlung von Benzaldehyd durch filamentöse Pilze |
EP1572116A4 (en) * | 2002-11-26 | 2007-12-12 | Genentech Inc | COMPOSITIONS AND METHODS FOR THE TREATMENT OF IMMUNE DISEASES |
JP2005328781A (ja) | 2004-05-21 | 2005-12-02 | Nagase Chemtex Corp | 新規ホスホリパーゼc |
CA2611143C (en) * | 2005-06-13 | 2014-03-11 | Novozymes A/S | Production of degummed fatty acid alkyl esters |
-
2006
- 2006-03-10 WO PCT/JP2006/304710 patent/WO2007105264A1/ja active Application Filing
- 2006-03-10 US US12/224,867 patent/US7993874B2/en active Active
- 2006-03-10 EP EP06728878.7A patent/EP1995313B1/en active Active
- 2006-03-10 EP EP11164069.4A patent/EP2368978B1/en active Active
- 2006-03-10 CN CN2006800537852A patent/CN101410513B/zh active Active
-
2011
- 2011-06-22 US US13/134,964 patent/US20110293786A1/en not_active Abandoned
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2000166543A (ja) | 1998-12-04 | 2000-06-20 | Shin Nippon Kagaku Kogyo Kk | ホスホリパーゼc及びその製造法 |
WO2004104193A2 (en) * | 2003-05-24 | 2004-12-02 | F2G Ltd | Phospholipase c |
Non-Patent Citations (35)
Title |
---|
"Biochemistry Data Book II", 23 June 1980, TOKYO KAGAKU DOJIN, pages: 1175 - 1259 |
ANDALUZ E. ET AL., YEAST, vol. 18, 2001, pages 711 - 721 |
ANDREW, L. NILES ET AL., BIOTECHNOL. APPL. BIOCHEM., vol. 28, 1998, pages 125 - 131 |
BENNETZEN, J. L.; HALL, B. D., J. BIOL. CHEM., vol. 257, 1982, pages 3018 - 3025 |
BIOCHEMISTRY, vol. 25, no. 25, 1986, pages 8274 - 8277 |
BIRCH M. ET AL.: "Evidence of multiple extracellular phospholipase activities of Aspergillus fumigatus", INFECT. IMMUNOL., vol. 64, no. 3, 1996, pages 751 - 755, XP002303872 * |
DAUGHERTY S. ET AL., INFECTION AND IMMUNITY, vol. 61, 1993, pages 5078 - 5089 |
EUR. J. BIOCHEM., vol. 163, 1987, pages 313 - 321 |
GLUZMAN, Y., CELL, vol. 23, 1981, pages 175 - 182 |
GRAHAM, F. L.; VAN DER EB, A. J, VIROLOGY, vol. 52, 1973, pages 456 - 457 |
GRANTHAM, R. ET AL., NUCLEIC ACIDS RES., vol. 9, 1981, pages 143 - 174 |
KIDD, I. M.; V. C. EMERY: "The use of baculoviruses as expression vectors", APPLIED BIOCHEMISTRY AND BIOTECHNOLOGY, vol. 42, 1993, pages 137 - 159, XP009055324, DOI: doi:10.1007/BF02788049 |
KORBSRISATE S. ET AL., JOURNAL OF CLINICAL MICROBIOLOGY, vol. 37, 1999, pages 3742 - 3745 |
KORNERUP, A.; WANSCHER, J. H.: "Methuen handbook of color", 1978, ERYE METHUEN, article "Methuen handbook of color" |
LAEMMLI, U.K, NATURE, vol. 227, 1970, pages 680 |
LUTHMAN, H.; MAGNUSSON, G., NUCLEIC ACIDS RES, vol. 11, 1983, pages 1295 - 1308 |
MARK, D. F. ET AL., PROC. NATL. ACAD. SCI., USA, vol. 81, 1984, pages 5662 - 5666 |
MATSUOKA S. ET AL., BIOTECHNOLOGY AND APPLIED BIOCHEMISTRY, vol. 9, 1987, pages 401 - 409 |
MATSUOKA S. ET AL.: "Purification and properties of a phospholipase C that has high activity toward sphingomyelin from Aspergillus saitoi", BIOTECHNOL. APPL. BIOCHEM., vol. 9, no. 5, 1987, pages 401 - 409, XP008122120 * |
MIYANOHARA, A. ET AL., PROC. NATL. ACAD. SCI., USA, vol. 80, 1983, pages 1 - 5 |
NEUMANN, E. ET AL., EMBO J., vol. 1, 1982, pages 841 - 845 |
OHMURA, K. ET AL., J. BIOCHEM., vol. 95, 1984, pages 87 - 93 |
PAYNE W. ET AL., MOLECULAR AND CELLULAR BIOLOGY, vol. 13, 1993, pages 4351 - 4364 |
SAMBROOK, J. ET AL.: "Molecular Cloning A Laboratory Manual", 1989, COLD SPRING HARBOR LABORATORY |
See also references of EP1995313A4 |
SOUTHERN, P. J.; BERG, P., J. MOL. APPL. GENET., vol. 1, 1982, pages 327 - 341 |
SUBRAMANI, S. ET AL., MOL. CELL. BIOL., vol. 1, 1981, pages 854 - 864 |
TAN C. ET AL., PROTEIN EXPRESSION AND PURIFICATION, vol. 10, 1997, pages 365 - 372 |
TITBALL R. ET AL., INFECTION AND IMMUNITY, vol. 57, 1989, pages 367 - 376 |
TOSHIMITSU KISHIMOTO ET AL., ZOKU-SEIKAGAKU JIKKEN KOUZA 1: IDENSHI KENKYUHO II, pages 335 - 354 |
TOSHIMITSU KISHIMOTO, SHIN-SEIKAGAKU JIKKEN KOUZA 2: KAKUSAN III KUMIKAE DNA GIJUTSU, pages 242 - 251 |
URLAUB, G.; CHASIN, L. A., PROC. NATL. ACAD. SCI., USA, vol. 77, 1980, pages 4126 - 4220 |
WANG, A. ET AL., SCIENCE, vol. 224, 1984, pages 1431 - 1433 |
WICKHAM, T. J. ET AL., BIOTECHNOL. PROG., vol. I, 1992, pages 391 - 396 |
ZHE-MEI WANG ET AL., BIOL. CHEM., vol. 379, 1998, pages 167 - 174 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102960770A (zh) * | 2012-12-07 | 2013-03-13 | 北京二商健力食品科技有限公司 | 一种速溶蛋黄粉及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN101410513A (zh) | 2009-04-15 |
EP1995313A1 (en) | 2008-11-26 |
EP1995313A4 (en) | 2010-04-07 |
EP2368978A1 (en) | 2011-09-28 |
EP1995313B1 (en) | 2013-05-08 |
US20110293786A1 (en) | 2011-12-01 |
US20090053768A1 (en) | 2009-02-26 |
CN101410513B (zh) | 2011-09-21 |
US7993874B2 (en) | 2011-08-09 |
EP2368978B1 (en) | 2014-04-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5179208B2 (ja) | グリセロ糖脂質リパーゼ | |
WO2007105264A1 (ja) | 新規ホスホリパーゼc | |
Brocca et al. | Design, total synthesis, and functional overexpression of the Candida rugosa lipl gene coding for a major industrial lipase | |
EP3119862B1 (en) | Polypeptides having phospholipase c activity and polynucleotides encoding same | |
JP2021508446A (ja) | 食品中のリン脂質の改善された酵素的修飾 | |
EP2020441B1 (en) | Novel lipase | |
JP4679923B2 (ja) | 新規ホスホリパーゼc | |
CN102174488A (zh) | 磷脂酶c及含其的食品用酶剂、以及食品原料的处理法 | |
JP5330334B2 (ja) | 食品用酵素剤 | |
CN106884008B (zh) | 磷脂酶、编码基因及其制备方法 | |
JP2017060424A (ja) | リパーゼ、ポリヌクレオチド、組換えベクター、形質転換体、リパーゼの製造法、グリセロ脂質を加水分解する方法及びグリセロ脂質の加水分解物を製造する方法 | |
EP1130100A1 (en) | Modified lipolytic enzymes and their use | |
RU2728240C1 (ru) | Способ получения секретируемой полностью функциональной фосфолипазы А2 в дрожжах Saccharomyces cerevisiae, белок-предшественник для осуществления этого способа (варианты) | |
JP5060666B2 (ja) | 酵素及びその製造方法 | |
EP2784160B1 (en) | Novel gene derived from mud flat metagenome and novel protein obtained therefrom showing coactivity of phospholipase and lipase | |
JP6013872B2 (ja) | ホスホリパーゼd、ポリヌクレオチド、ホスホリパーゼdの製造方法、コリン型プラズマローゲンの測定方法、リゾホスファチジルコリンの測定方法、リゾホスファチジン酸の製造方法 | |
WO2012105565A1 (ja) | 酵素及びその製造方法 | |
JP6063207B2 (ja) | グリセロール−3−ホスホコリン(gpc)などのグリセロール−3−ホスホジエステルに対して加水分解作用を有する酵素及びその製造方法 | |
WO2024015974A1 (en) | Improved enzymatic modification of phospholipids in food | |
KR100444948B1 (ko) | 세포외 포스포리파제 d를 생산하는 신규한 스트렙토마이세스 속 yu100 균주 및 이의 용도 | |
JP2012196175A (ja) | バイオディーゼル燃料の製造方法 | |
AU2012201152A1 (en) | Novel lipase |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 06728878 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12224867 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200680053785.2 Country of ref document: CN |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006728878 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: JP |